Published in Hepatitis Weekly, May 30th, 2005
Third Wave reported total revenues of $7.1 million and a net loss of $4.4 million, or ($0.11) per diluted share, for the quarter ended March 31, 2005, compared to total revenues of $15.3 million and net income of $2.8 million, or $0.07 per diluted share, for the same period of 2004.
The company reported clinical molecular diagnostic revenue of $3.1 million for the first quarter of 2005. U.S. clinical revenue increased 15% over the prior-year period. The sequential quarter-to-quarter decline in clinical revenue was due to the timing of large...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly